Latest Galectin Stories

2012-01-22 18:00:00

La Jolla acquires GCS-100 for treatment of cancer and chronic organ failure, appoints new CEO and director Scottsdale, AZ (PRWEB) January 22, 2012 QualityStocks would like to highlight La Jolla Pharmaceutical Co., a publicly traded biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company´s product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular...

2009-06-15 08:00:00

WELLESLEY HILLS, Mass., June 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that in vitro studies have demonstrated that GCS-100 binds to and blocks the effects of galectin-3. Galectin-3 plays an important role in tumor cell survival, new blood vessel growth, cell proliferation and tumor metastasis, which is the spread of cancer beyond its primary site. As a result, this product candidate may have multiple benefits in combating cancer cells, including: Induction...

Word of the Day
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'